%0 Journal Article
%A White, Christine L
%A Kinross, Kathryn M
%A Buntine, Molly K
%A Rasouli, Elnaz
%A Strong, Robyn
%A Jones, Janelle M
%A Cain, Jason E
%A Sturm, Dominik
%A Sahm, Felix
%A Jones, David T W
%A Pfister, Stefan M
%A Robertson, Thomas
%A D'Arcy, Colleen
%A Rodriguez, Michael L
%A Dyke, Jason M
%A Junckerstorff, Reimar
%A Bhuva, Dharmesh D
%A Davis, Melissa J
%A Wood, Paul
%A Hassall, Tim
%A Ziegler, David S
%A Kellie, Stewart
%A McCowage, Geoffrey
%A Alvaro, Frank
%A Kirby, Maria
%A Heath, John A
%A Tsui, Karen
%A Dodgshun, Andrew
%A Eisenstat, David D
%A Khuong-Quang, Dong-Anh
%A Wall, Meaghan
%A Algar, Elizabeth M
%A Gottardo, Nicholas G
%A Hansford, Jordan R
%T Implementation of DNA methylation array profiling in pediatric central nervous system tumors - the AIM BRAIN Project: an Australian and New Zealand Children's Haematology and Oncology (ANZCHOG) Group study.
%J The journal of molecular diagnostics
%V 25
%N 10
%@ 1525-1578
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2023-01550
%P 709-728
%D 2023
%Z 2023 Oct;25(10):709-728
%X DNA methylation array profiling for classifying pediatric central nervous system (CNS) tumors is a valuable adjunct to histopathology. However, unbiased prospective and inter-laboratory validation studies have been lacking. The AIM BRAIN (AB) diagnostic trial involving 11 pediatric cancer centers in Australia and New Zealand was designed to test the feasibility of routine clinical testing and ran in parallel with the Molecular Neuropathology 2.0 (MNP2.0) study at Deutsches Krebsforschungszentrum (DKFZ) (German Cancer Centre Heidelberg, Germany). CNS tumors from 269 pediatric patients were prospectively tested on Illumina EPIC arrays including 104 cases co-enrolled on MNP2.0. Using MNP classifier versions 11b4 and 12.5, we report classifications with a probability score ≥ 0.90 in 176/265 (66.4
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37517472
%R 10.1016/j.jmoldx.2023.06.013
%U https://inrepo02.dkfz.de/record/277882